tiprankstipranks
Trending News
More News >

Aptevo Therapeutics Regains Nasdaq Compliance with Equity Raise

Story Highlights
Aptevo Therapeutics Regains Nasdaq Compliance with Equity Raise

Don’t Miss TipRanks’ Half-Year Sale

Aptevo Therapeutics ( (APVO) ) has provided an update.

Aptevo Therapeutics Inc. announced that it has regained compliance with Nasdaq’s listing requirements as of July 1, 2025, after previously being non-compliant due to insufficient stockholders’ equity. The company achieved compliance by raising approximately $15.9 million in additional equity capital during the quarter ended June 30, 2025, ensuring its stockholders’ equity meets the necessary threshold.

The most recent analyst rating on (APVO) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.

Spark’s Take on APVO Stock

According to Spark, TipRanks’ AI Analyst, APVO is a Underperform.

Aptevo Therapeutics’ stock score is significantly impacted by its challenging financial performance, marked by declining revenues, high leverage, and negative cash flows. The technical analysis indicates bearish momentum, while the valuation is weakened by persistent losses. However, promising developments in its oncology pipeline offer potential upside if successfully executed.

To see Spark’s full report on APVO stock, click here.

More about Aptevo Therapeutics

Aptevo Therapeutics Inc. operates in the biotechnology industry, focusing on developing novel immuno-oncology and hematology therapeutics.

Average Trading Volume: 2,450,935

Technical Sentiment Signal: Strong Sell

Current Market Cap: $9.93M

See more insights into APVO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1